ArticleTranslational pediatrics2026
Precision myeloablation with TDM-guided busulfan in pediatric primary immunodeficiencies: a real-world study of 28 patients.
Article in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Optimizing busulfan (Bu) exposure is critical for balancing engraftment and toxicity in pediatric patients with primary immunodeficiencies (PID) undergoing hematopoietic stem cell transplantation (HSCT). This study evaluates the outcomes of a therapeutic drug monitoring (TDM)-guided, personalized Bu/fludarabine (Flu) regimen. Methods: We retrospectively analyzed 28 pediatric PID patients [11 severe combined immunodeficiency (SCID) and 17 with non-SCID] who underwent first allogeneic HSCT (allo-HSCT) between March 2022 and September 2025. All patients received Flu (150-180 mg/m Results: Only 11/28 patients (39.3%) achieved target AUC after the first Bu dose, confirming the necessity of TDM. With a median follow-up of 829.5 days [interquartile range (IQR), 376-1,046 days], 2-year OS and EFS were 96.42%. Sustained engraftment with complete or high-level donor chimerism was achieved in 96.42% of patients. Severe RRT was minimal: grade 3-4 mucositis (n=1, 3.5%) and definite veno-occlusive disease (VOD) (n=1). No grade 3-4 acute GVHD occurred. Chronic GVHD (cGVHD) occurred in 7/27 patients (25.9%), predominantly pulmonary-limited. Cytomegalovirus (CMV) reactivation occurred in 11 patients (39.2%) without CMV disease. All surviving patients discontinued immunoglobulin replacement within one year. Conclusions: A risk-adapted, TDM-guided Bu/Flu conditioning regimen achieves an optimal balance between efficacy and toxicity in pediatric PID HSCT. With a 2-year OS of 96.4%, minimal severe RRT, and universal intravenous immunoglobulin (IVIG) independence by 12 months, this precision myeloablative approach should be considered the preferred standard for this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.